This story was originally posted on July 27.

By Justin Petrone

Illumina last week reported a 36-percent spike in second-quarter revenues driven by "strong demand" for its next-generation sequencing products and restored growth in its array business, particularly for whole-genome genotyping chips.

It also said it expects full-year 2011 revenue to increase as much as 26 percent over 2010, causing annual revenue to hit the billion-dollar mark for the first time in its history.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.